塞來昔布對人結腸癌細胞生長及裸鼠肝轉移瘤形成的影響_《中國普外基礎與臨床雜志》

作者：

劉偉 ¹ , 安杰 ² , 張超 ¹ , 劉占奎 ¹

1.第三軍醫大學西南醫院普外科(重慶 400038);;
2.白求恩國際和平醫院病理科(石家莊050082);

關鍵詞：

結腸癌環氧合酶塞來昔布

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目的　探討塞來昔布對體外培養的結腸癌細胞生長及裸鼠肝轉移瘤的影響。方法　以人結腸癌細胞株HT-29（COX-2高表達）和HCT-116（COX-2低表達）為研究對象，采用噻唑藍（MTT）比色法檢測塞來昔布對2種細胞的增殖抑制效應，應用流式細胞術檢測2種細胞的周期分布情況；將2種細胞接種裸鼠，觀察其肝轉移瘤形成情況。結果　①塞來昔布對人結腸癌細胞株生長的抑制作用呈時間、劑量依賴性效應（P＜0.05, P＜0.01），且對HT-29細胞的作用強于HCT-116細胞（P＜0.05）。②塞來昔布可改變結腸癌細胞株細胞周期的分布，明顯降低其增殖指數。③塞來昔布具有明顯的抑制裸鼠肝轉移瘤生長的作用。結論　塞來昔布可能通過抑制COX-2酶活性而抑制結腸癌細胞的分裂和增殖，誘導其凋亡，干預結腸癌的轉移與復發。

引用本文： 劉偉,安杰,張超,劉占奎. 塞來昔布對人結腸癌細胞生長及裸鼠肝轉移瘤形成的影響. 中國普外基礎與臨床雜志, 2006, 13(6): 693-697. doi: 復制

1.	Tomozawa S, Tsuno NH, Sunami E, et al. Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer [Ｊ]. Cancer，2000; 83(3)∶ 324.
2.	Kakiuchi Y, Tsuji S, Tsujii M, et al. Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens on colon cancer cells and enhanced liver metastasis [Ｊ]. Cancer Res， 2002; 62(5)∶1567.
3.	DuBois RN, Radhika A, Reddy BS, et al. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors [Ｊ]. Gastroenterology, 1996; 110(4)∶1259.
4.	Williams CS, Luongo C, Radhika A, et al. Elevated cyclooxygenase-2 levels in Min mouse adenomas [Ｊ]. Gastroenterology， 1996; 111(4)∶1134.
5.	Takeuchi K, Tanaka A, Ohno R, et al. Role of COX inhibition in pathogenesis of NSAID-induced small intestinal damage [Ｊ]. J Physiol Pharmacol， 2003; 54(Suppl 4)∶165.
6.	Herschman HR. Regulation of prostaglandin synthase-1 and prostaglandin synthase-2 [Ｊ]. Cancer Metastasis Rev， 1994; 13(3－4)∶241.
7.	Shattuck-Brandt RL, Varilek GW, Radhika A, et al. Cyclooxygenase 2 expression is increased in the stroma of colon carcinomas from IL-10(-/-) mice [Ｊ]. Gastroenterology. 2000; 118(8)∶337.
8.	Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology [Ｊ]. Annu Rev Biochem， 2000; 69∶145.
9.	Pyrko P, Soriano N, Kardosh A, et al. Downregulation of survivn expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo [Ｊ]. Mol Cancer, 2006; 5∶19.
10.	朱建民, 曾　明. 環氧化酶和非甾體類消炎藥 [Ｊ]. 中國新藥與臨床雜志， 2001; 20（3）∶208.
11.	Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2 [Ｊ]. Cell, 1995; 83(3)∶493.
12.	Weber A, Casini A, Heine A, et al. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition [Ｊ]. J Med Chem， 2004; 47(3)∶550.
13.	Momin RA, De Witt DL, Nair MG. Inhibition of cyclooxygenase (COX) enzymes by compounds from Daucus carota L. Seeds [Ｊ]. Phytother Res, 2003; 17(8)∶976.
14.	Liu W, Chen Y, Wang W, et al. Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth [Ｊ]. Am J Clin Oncol, 2003; 26(4)∶S103.
15.	Jacoby RF, Cole CE, Tutsch K, et al. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos [Ｊ]. Cancer Res, 2000; 60(7)∶1864.
16.	吳高松, 劉正人, 鄒聲泉, 等. 塞來昔布(celecoxib)通過前列腺素E2途徑影響膽管癌細胞株生長和凋亡 [Ｊ]. 外科理論與實踐, 2003; 8(2)∶137.
17.	Gately S. The contribution of cyclooxygenase-2 to tumor angiogenesis [Ｊ]. Cancer Metastasis Rev, 2001； 19(1－2)∶19.
18.	Wu GS, Wang JH, Liu ZY, et al. Expression of cyclooxygenase-1 and -2 in extra-hepatic cholangiocarcinoma [Ｊ]. HBPD INT, 2002; 1(3)∶429.
19.	Yao M, Kargman S, Lam EC, et al. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice [Ｊ]. Cancer Res, 2003; 63(3)∶586.

1. 　Tomozawa S, Tsuno NH, Sunami E, et al. Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer [Ｊ]. Cancer，2000; 83(3)∶ 324.
2. 　Kakiuchi Y, Tsuji S, Tsujii M, et al. Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens on colon cancer cells and enhanced liver metastasis [Ｊ]. Cancer Res， 2002; 62(5)∶1567.
3. 　DuBois RN, Radhika A, Reddy BS, et al. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors [Ｊ]. Gastroenterology, 1996; 110(4)∶1259.
4. 　Williams CS, Luongo C, Radhika A, et al. Elevated cyclooxygenase-2 levels in Min mouse adenomas [Ｊ]. Gastroenterology， 1996; 111(4)∶1134.
5. 　Takeuchi K, Tanaka A, Ohno R, et al. Role of COX inhibition in pathogenesis of NSAID-induced small intestinal damage [Ｊ]. J Physiol Pharmacol， 2003; 54(Suppl 4)∶165.
6. 　 Herschman HR. Regulation of prostaglandin synthase-1 and prostaglandin synthase-2 [Ｊ]. Cancer Metastasis Rev， 1994; 13(3－4)∶241.
7. 　Shattuck-Brandt RL, Varilek GW, Radhika A, et al. Cyclooxygenase 2 expression is increased in the stroma of colon carcinomas from IL-10(-/-) mice [Ｊ]. Gastroenterology. 2000; 118(8)∶337.
8. 　Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology [Ｊ]. Annu Rev Biochem， 2000; 69∶145.
9. 　Pyrko P, Soriano N, Kardosh A, et al. Downregulation of survivn expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo [Ｊ]. Mol Cancer, 2006; 5∶19.
10. 　朱建民, 曾　明. 環氧化酶和非甾體類消炎藥 [Ｊ]. 中國新藥與臨床雜志， 2001; 20（3）∶208.
11. 　Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2 [Ｊ]. Cell, 1995; 83(3)∶493.
12. 　Weber A, Casini A, Heine A, et al. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition [Ｊ]. J Med Chem， 2004; 47(3)∶550.
13. 　Momin RA, De Witt DL, Nair MG. Inhibition of cyclooxygenase (COX) enzymes by compounds from Daucus carota L. Seeds [Ｊ]. Phytother Res, 2003; 17(8)∶976.
14. 　Liu W, Chen Y, Wang W, et al. Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth [Ｊ]. Am J Clin Oncol, 2003; 26(4)∶S103.
15. 　Jacoby RF, Cole CE, Tutsch K, et al. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos [Ｊ]. Cancer Res, 2000; 60(7)∶1864.
16. 　吳高松, 劉正人, 鄒聲泉, 等. 塞來昔布(celecoxib)通過前列腺素E2途徑影響膽管癌細胞株生長和凋亡 [Ｊ]. 外科理論與實踐, 2003; 8(2)∶137.
17. 　Gately S. The contribution of cyclooxygenase-2 to tumor angiogenesis [Ｊ]. Cancer Metastasis Rev, 2001； 19(1－2)∶19.
18. 　Wu GS, Wang JH, Liu ZY, et al. Expression of cyclooxygenase-1 and -2 in extra-hepatic cholangiocarcinoma [Ｊ]. HBPD INT, 2002; 1(3)∶429.
19. 　Yao M, Kargman S, Lam EC, et al. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice [Ｊ]. Cancer Res, 2003; 63(3)∶586.

《中國普外基礎與臨床雜志》

塞來昔布對人結腸癌細胞生長及裸鼠肝轉移瘤形成的影響

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《中國普外基礎與臨床雜志》

塞來昔布對人結腸癌細胞生長及裸鼠肝轉移瘤形成的影響

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料